Literature DB >> 33036727

Multivisceral resection for locally advanced gastric cancer: A retrospective study.

Yanpeng Yang1, Jianwen Hu1, Yongchen Ma1, Guowei Chen2, Yucun Liu3.   

Abstract

BACKGROUND: Multivisceral resection may be the exclusive radical procedure for cT4b gastric cancer patients. However, most surgeons refuse to select surgery because of the theoretical higher mortality, morbidity and poorer prognosis.
METHODS: We retrospectively reviewed cT4b gastric cancer patients who underwent surgery from January 1,1997 to December 31,2018. The primary endpoint was overall survival. Short-term results and prognostic values of clinical and pathologic factors were also analyzed.
RESULTS: Patients underwent multivisceral resection had an acceptable mortality and morbidity. The overall 5-year survival rate of multivisceral resection was higher than that of palliative surgery (P < 0.05). And independent prognostic factors of multivisceral resection were R+ resection, extensive lymph node involved (>15), vascular cancer emboli, and postoperative chemotherapy.
CONCLUSIONS: cT4b gastric cancer patients underwent multivisceral resection experience acceptable mortality and morbidity. The independent prognostic factors for multivisceral resection were completeness of resection, extensive lymph node involvement (>15), vascular cancer emboli, and postoperative chemotherapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multivisceral resection; Prognostic factors; Survival rate; T4b gastric Cancer

Year:  2020        PMID: 33036727     DOI: 10.1016/j.amjsurg.2020.09.037

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Short-term safety and Long-term efficacy of multivisceral resection in pT4b gastric cancer patients without distant metastasis: a 20-year experience in China National Cancer Center.

Authors:  Xiaojie Zhang; Wanqing Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Dongbing Zhao; Yingtai Chen
Journal:  J Cancer       Date:  2022-08-15       Impact factor: 4.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.